Format

Send to

Choose Destination
Tob Control. 2018 Nov;27(Suppl 1):s20-s25. doi: 10.1136/tobaccocontrol-2018-054296. Epub 2018 Aug 29.

Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.

Author information

1
Department of Medicine, University of California San Francisco, San Francisco, California, USA.
2
Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA.
3
Department of Anesthesia, University of California San Francisco, San Francisco, California, USA.

Abstract

INTRODUCTION:

Heated tobacco products are being touted as novel reduced-harm tobacco products by tobacco companies. In the USA, Philip Morris International submitted a modified risk tobacco product (MRTP) application to the US Food and Drug Administration in 2016 in which it purports that its heated tobacco product, I-Quit-Ordinary-Smoking (IQOS), is associated with reduced harm compared with conventional cigarettes.

METHODS:

We reviewed Philip Morris International's MRTP application to assess the pulmonary and immune toxicities associated with IQOS use in both animal and human studies.

RESULTS:

Among rats exposed to IQOS, there was evidence of pulmonary inflammation and immunomodulation. In human users, there was no evidence of improvement in pulmonary inflammation or pulmonary function in cigarette smokers who were switched to IQOS.

CONCLUSION:

IQOS is associated with significant pulmonary and immunomodulatory toxicities with no detectable differences between conventional cigarette smokers and those who were switched to IQOS in Philip Morris International's studies. Philip Morris International also failed to consider how dual use and secondhand aerosol exposure may further impact, and likely increase, the harms associated with these products.

KEYWORDS:

non-cigarette tobacco products; tobacco industry; toxicology

Free full text

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center